Strong cell-type-specific promoters are basic tools in gene therapy allowing for novel applications and focused strategies by transcriptionally targeting gene expression to selected cells. In immunotherapy, dendritic cells (DC) are of central importance, since they represent the principal inducers of immune responses. Here we describe isolation and use of the promoter of the murine actin-bundling protein fascin to target transcriptionally gene expression to cutaneous DC. Using the reporter gene enhanced green fluorescent protein (EGFP), we demonstrate that the fascin promoter mediates a strong antigen expression that is restricted to mature DC. DNA vaccination with antigenencoding expression vectors under control of the fascin promoter using a gene gun resulted, consistently, in limited antigen expression by few directly transfected DC. Nevertheless, nearly as many antigen-specific CD8 + T cells directed against the encoded antigens EGFP and bgalactosidase, respectively, were induced as with expression constructs under control of the ubiquitously expressed CMV promoter. This result impressively underlines the pivotal role of directly transfected DC in DNA vaccination. Immunization using the fascin promoter induced markedly lower levels of antigen-specific antibodies following single or repeated immunization. Thus, our DC-targeted DNA vaccination approach induces qualitatively distinct, predominantly cellular immune responses and provides new opportunities for immunotherapy.
Immature dendritic cells (DC) like epidermal Langerhans cells represent sentinel cells of the immune system residing in nearly all peripheral organs. They take up antigen and, once activated by inflammatory stimuli, leave peripheral tissues via lymph vessels to enter the Tcell areas of draining lymph nodes. There they interact with T cells by presenting processed antigen peptides via major histocompatibility (MHC) molecules to T cells and provide, if full maturation was induced, all necessary costimulatory signals required for efficient activation of naive T cells (for a review see Banchereau and Steinman 1 ). Owing to their primary stimulatory capacity in the mature state and their unique migratory behavior, DC are crucial for elicitation of T helper cell-dependent humoral as well as cytotoxic T cell immune responses. Accordingly, transfer experiments show that in vitro transfected DC elicit immune reactions in vivo, 2,3 while other cells fail to do so 3 unless they are injected directly into lymphoid tissues. 4 Antigen presentation by keratinocytes alone leads to immunological unresponsiveness. 5, 6 The aim of the present study was to isolate a strong cell-type-specific promoter to target gene expression to mature DC for use in gene therapy. In the preceeding work, we analyzed differential gene expression in maturing DC and identified several genes of functional importance, which are selectively expressed by mature DC and only very few other cell types. 7, 8 For a detailed analysis, we isolated the promoter of one of these genes, encoding the actin-bundling protein fascin. This structural protein crosslinks actin filaments and was shown by us to be pivotal for dendrite formation in DC. 7, 9 The following characteristics of fascin expression suggested that the promoter might be useful to transcriptionally target production of transgenes to mature DC: (1) As a structural protein fascin is abundantly produced, promising high expression levels of genes under the control of the fascin promoter. (2) Fascin synthesis is switched on during maturation of DC in mouse and man, 7, 9 directing expression of transgenes to fully mature, primary stimulatory DC. (3) Expression of fascin in nontransformed cell types other than DC is restricted to neuronal tissues, capillary endothelial cells and, possibly, to follicular DC. 7, 10 It should, therefore, be possible to restrict expression of transgenes to DC using fascin promoter-driven expression constructs, for example, by DNA vaccination via the skin. DNA vaccination using a gene gun is an efficient method to elicit cellular as well as humoral immune responses Figure 1 Cloning and analysis of the specificity of the murine fascin promoter in vitro. (a) An arrayed genomic library derived from C57BL/6 mice obtained from the 'Resource Centre of the German Human Genome Project' (RZPD, Berlin) was screened as described 24 with a mouse fascin cDNA probe. A 3.5 kb Pvu II-fragment (pPvu II-fascin), encompassing the promoter region and part of exon 1 (Ex 1) of the fascin gene was subcloned, mapped for the restriction sites Bam H1 (B), Bg lII (Bg), Pst I (P), Pvu I (Pv) and Xba I (X) and sequenced completely (Accession .Number: AJ318756). A 2.6 kb promoter fragment including part of the transcribed but nontranslated sequence of the fascin gene was subcloned into vector pCI (Promega, Mannheim, Germany). The coding sequence of either EGFP (derived from plasmid pEGFP-N1, BD Biosciences CLONTECH, Heidelberg, Germany) or b-galactosidase (derived from pCMVb, BD Biosciences CLONTECH) was inserted to drive the expression of EGFP (pFascin-EGFP) or b-galactosidase (pFascin-bGal) under control of the fascin promoter. The polyadenylation site (pA) of pCI, derived from SV40, is marked. (b) DC2.4 cells were transfected with pCI-based expression vectors, driving synthesis of EGFP under control of the fascin promoter (pFascin-EGFP) or the cytomegalovirus immediate-early promoter (pCMV-EGFP). Cells were analyzed for EGFP expression 24 h following transfection by fluorescence microscopy using a BX50WI microscope (Olympus, Hamburg, Germany). (c) The DC lines DC2.4 and XS52 were transfected with p-EGFP (pCI-based expression vector harboring the EGFP coding region but without any promoter driving its expression), with pCMV-EGFP or with pFascin-EGFP. EGFP expression of transfected cells was analyzed by cytofluorometry using a FACSscan (Becton Dickinson, Heidelberg, Germany). Chanel FL1 (EGFP + cells, EGFP) is plotted against sidewards scatter (SSC). EGFP + cells are located in the gate on the right-hand side of the plots. Corresponding numbers of EGFP + cells are indicated within the gate of each plot. For transfection, GenePORTER reagent (Gene Therapy Systems, San Diego, CA, USA) was used following the recommendations of the manufacturer. Based on optimization experiments 1 mg DNA and 5 ml (DC2.4) or 8 ml (XS52) GenePORTER, respectively, were used.
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R Ross et al against plasmid-encoded antigens. 11 Microscopic gold particles with noncovalently attached antigen-encoding plasmid DNA are accelerated by helium pressure, penetrate the surface of the skin and transfect skin cells. The transfected cells, because of high abundance mainly keratinocytes and only few DC, express the encoded antigen, and immune responses against this antigen are elicited. Transfection of the DC was, however, demonstrated to be pivotal for the induction of immune responses following DNA vaccination.
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Figure 2 The murine fascin promoter is suited to transcriptionally target langerin/CD207-positive LC in vivo. Ear skin of BALB/c mice was transfected by biolistic transfer of 4 mg pFascin-EGFP and pCMV-EGFP, respectively, using a gene gun (Heliost, BioRad, Hercules, CA, USA) according to the recommendations of the manufacturer. Mice were killed 24 h following biolistic particle bombardment and transfected ears as well as draining lymph nodes were taken. Cross-sections of transfected ears (a-d) were analyzed for langerin expression, using the monoclonal anti-langerin antibody 929F3, and for EGFP expression (a: pCMV-EGFP, EGFP; b: pCMV-EGFP, langerin; c: pFascin-EGFP, EGFP; d: pFascin-EGFP, langerin). Arrows in (c) and (d) mark a cell that is positive for both, EGFP and langerin. Note that langerin + LC in (b) and (d) emigrate preferentially from the transfected epidermis (upper site) but not from the opposite nontransfected epidermal layer (lower site). Cytospins of lymph node cells from pFascin-EGFP transfected mice (e-g). A transfected cell harboring a gold particle (e, arrow) is positive for langerin (f) and EGFP (g). Langerin + EGFP À cells but no langerin À EGFP + cells were detected (not shown). As a control of specificity of immunofluorescence analysis, a CD86 À EGFP + cell line was mixed with a CD86 + EGFP À cell line and cytospins were stained for CD86 (h).
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To test the fascin promoter in this system, we first isolated the fascin gene from a genomic library derived from C57BL/6 mice using fascin cDNA as a probe. Partial sequencing and restriction mapping ensured that the clone isolated encompasses the complete fascin gene and several kb of flanking sequences. A 3.5 kb subclone was sequenced completely. By comparison with the 5 0 -ends of several fascin cDNA sequences obtained from our differential screenings 7 and from the EMBL database, we identified the putative transcriptional start site. As hallmarks of a typical promoter, we identified stretches of GC-rich sequences and consensus binding sites for several transcription factors, including a consensus TATA box in appropriate distance from the putative transcriptional start site. Based on these data, the coding sequence of the reporter genes enhanced green fluorescent protein (EGFP) and b-galactosidase were set under control of a 2.6 kb fascin promoter fragment and inserted into pCI (Promega, Mannheim, Germany), thereby replacing the CMV promoter of pCI (pFascin-EGFP and pFascin-bGal, Figure 1a) .
To analyze the activity of the fascin promoter, pFascin-EGFP was transfected into cells in vitro and in vivo. In parallel, an EGFP construct under the control of the cytomegalovirus immediate-early promoter (pCMV-EGFP) was used for transfections. EGFP expression was monitored by fluorescence microscopy and cytofluorometry. By fluorescence microscopy, strong EGFP expression was detected with pFascin-EGFP in the murine cell line DC2.4 (Figure 1b) , which had been characterized to be of mature DC phenotype.
14 In contrast, no EGFP expression was observed with pFascin-EGFP in XS52 cells, a DC line of immature phenotype 15 (data not shown). Using cytofluorometry, Detection of antigen-specific IgG antibodies. Sera were recovered from the retro-orbital plexus of immunized mice and EGFP-specific or b-galactosidase-specific IgG was measured by ELISA as described 25 with the modification that recombinant EGFP (2 mg/ml; BD Biosciences CLONTECH) or b-galactosidase (5 mg/ml; Sigma-Aldrich) was used as antigen. The antibody titer was defined as the reciprocal serum dilution, yielding an absorbance value of OD¼0.2 after linear regression analysis. The mean7s.d. is presented. Left: EGFP-specific IgG in the sera of mice (n¼3) transfected with pCMV-EGFP and pFascin-EGFP, respectively, was measured on day 56. Right: b-galactosidase-specific IgG in the sera of mice (n¼4-8) transfected with pCMV-bGal and pFasin-bGal, respectively, was measured on day 46. Data are representative of at least three independent experiments. Statistically significant differences (*Po0.05, **Po0.01) between pFascin and pCMV immunized mice as evaluated by Student's t-test using Sigma Plot software are indicated. (Figure 2e-g ), discouraging the view that langerinnegative dermal DC had been transfected. Taken together, the fascin promoter is suited to transcriptionally target epidermal LC, which, as shown before, using the ELISPOT technique (Figure 3a) . Such EGFPpeptide-specific CD8 + T cells, induced by DNA vaccination, had been shown to represent cytotoxic T lymphocytes. 17 Notably, comparable numbers of antigen-reactive CD8 + effector T cells were induced with both constructs following one single vaccination (P¼0.3), despite the drastically lower number of EGFP-expressing cells in the skin of pFascin-EGFP-treated versus pCMV-EGFP-treated mice. Even after three rounds of vaccination, the number of IFN-g-producing CD8
+ T cells was only slightly lower using pFascin-EGFP. Similar results were obtained from analogous DNA vaccinations using pFascin-bGal with bgalactosidase as an antigen (Figure 3a) . In contrast to the cellular immune response, major differences between mice transfected with pCMV-EGFP and pFascin-EGFP were observed, when analyzing levels of EGFP-specific IgG (Figure 3b) . Low, but significant, EGFP-specific IgG titers were detected in the sera of mice following one single immunization with pCMV-EGFP, while production of EGFP-specific IgG following transfection of pFascin-EGFP was barely above the detection limit. Repeated immunization with pCMV-EGFP tremendously boosted the production of EGFP-specific IgG, whereas the increase in IgG antibody titers after three consecutive immunizations with pFascin-EGFP was only weak. Again, comparable results were obtained with pFascin-bGal (Figure 3b) .
Taken together, the murine fascin promoter was successfully used to target DC in DNA vaccination and offers new opportunities for gene therapy. Our data confirm and extend previous findings indicating that DCtargeted DNA vaccination preferentially induces cellular immune responses. Some of us have reported that mice immunized with DC, which had been transduced in vitro with a recombinant adenovirus encoding EGFP, also developed a predominantly cellular immune response against EGFP. 18 Furthermore, Morita et al 19 recently used the murine dectin-2 promoter to target EGFP expression to DC applying DNA vaccination. Splenocytes from transfected mice showed enhanced cell proliferation and augmented IFN-g production in response to recombinant EGFP. The authors detected no EGFP peptidespecific antibodies as analyzed by immunoblotting. We add new information to this picture showing that transgene-specific IFN-g-producing CD8
+ T cells are induced by DC-targeted DNA vaccination and that the number of these cells is comparable to the number of transgene-specific CD8 + T cells induced in mice transfected with CMV promoter-driven constructs. In addition, we detected low but significant amounts of transgene-specific antibodies; this finding may be because of a higher sensitivity of the assay used or because of the fact that the fascin promoter is stronger than the dectin-2 promoter. Morita et al 19 compared the activity of the dectin-2 promoter with the SV40 promoter and observed a relative expression level similar to the relative expression level we observed using the much stronger CMV promoter for comparison. Cho et al 20 used the antigen-presenting cell-specific CD11b promoter for DNA immunization and identified low but significant amounts of antigen-specific antibodies as well. Brocker et al. 21 employed the CD11c promoter to target expression of MHC class II I-E molecules to DC. All these various promoters have individual characteristics. Special features of the fascin promoter are the high gene expression level in DC and restriction of expression to mature DC. The latter is of importance for the induction of immune responses as mature DC induce novel immune responses, while immature DC were shown to induce anergy. 22 Considering that DNA vaccination is currently being broadly tested in clinical trials, we believe that our fascin promoter-based vaccination approach offers significant opportunities, especially when cellular immune responses are curative. Importantly, we isolated the human fascin promoter, which shows very similar characteristics (manuscript in preparation) and allows for the first time transcriptional targeting of DC in human gene therapy.
Furthermore, our system is ideally suited to study the mechanisms underlying induction of cellular and humoral immune responses following DNA vaccination. DC-targeted DNA vaccination differs in some aspects from conventional DNA vaccination, which might explain the reduced humoral response observed: (1) The amount of antigen synthesized is drastically reduced. Most transfected cells are non-DC (mainly keratinocytes) and do not express the antigen after vaccination transcriptionally targeting DC. Following conventional DNA vaccination, nonsecreted proteins like EGFP and b-galactosidase expressed by keratinocytes will be retained intracellularly until the cells die. The (3) Owing to the low number of antigen-expressing cells, cross-presentation of antigen to DC appears to play a minor role.
The contribution of these factors to the outcome of the immune response will be addressed in future experiments. Furthermore, the fascin promoter will prove to be very useful to investigate the biological functions of DC in vivo. This may lead to the development of novel applications for DC-based immunotherapy.
